Clinical trials: Molecular Targeted Therapies
Cancer, Tumors
The Drug Rediscovery Protocol (DRUP Trial)
This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs* prescribed for treatment of patients with advanced cancer with a…
- Conditions
- Cancer, Tumors, Neoplasm, Neoplasia
- Trial name
- DRUP (NCT02925234)
- Testing
- Panitumumab, Olaparib, Dabrafenib
- Where
- 36 sites in Netherlands
- Volunteers
- 1,550 people
- Sponsor
- The Netherlands Cancer Institute
Brain Neuroimaging Biomarkers in Huntington Disease
Dynamic Neuroimaging Biomarkers in Huntington's Disease
There is no curative treatment available today in Huntington disease (HD) despite the identification of the mutated gene 20 years ago.
- Trial name
- HDeNERGY (NCT02639871)
- Where
- France
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Unresectable Metastatic Colorectal Cancer
mXELOXIRI Combined With Molecular Targeted Drug in mCRC
The objective is to evaluate the efficacy and safety of modified XELOXIRI combined with molecular targeted drug as first-line therapy in patients with metastatic colorectal cancer (mCRC)
- Trial name
- TRICAP (NCT04160416)
- Testing
- Capecitabine-Oxaliplatin-Irinotecan Combination
- Where
- China
- Volunteers
- 48 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Neuroblastoma Recurrent
Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma
Children, adolescents and young adults with high risk relapsed or treatment refractory neuroblastoma (rNB) represent a group of patients with dismal prognosis for whom a recommended standard salvage therapy is currently not…
- Trial name
- RIST-rNB-2011 (NCT01467986)
- Testing
- Dasatinib, Rapamycin, Irinotecan
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- University of Regensburg
Leukemia
Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia
RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00896766
- Testing
- loss of heterozygosity analysis, microarray analysis, polymorphism analysis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Medical Oncology, Hematology
Onco-haematology Vigilance Card
The objective of this study is to show the interest of setting up a drug vigilance card in Oncology in order to reinforce patient safety, develop compliance and avoid drug interactions when the patient consults town professionals…
- Conditions
- Medical Oncology, Hematology, Molecular Targeted Therapies
- Trial name
- THERANOVA-LIM (NCT04931329)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Limoges
Progression Free Survival
Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients
Treatment options for patients with colorectal cancer (CRC) have increased in the last years. However, there are no validated prospective molecular markers in CRC to select which agents are better to treat any individual case.
- Trial name
- TT (NCT01453257)
- Testing
- Tailored Chemotherapy
- Where
- Spain
- Volunteers
- 72 people
- Sponsor
- Grupo Hospital de Madrid
Human Papillomavirus-Related Malignant Neoplasm
Study of Molecular-targeted Therapy Using Zinc Finger Nuclease in Cervical Precancerous Lesions
This research study is being carried out to study a new way to possibly treat human cervical intraepithelial neoplasia (CIN) without invasion.
- Trial name
- NCT02800369
- Testing
- ZFN-603 and ZFN-758
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Huazhong University of Science and Technology
Metastatic Solid Tumors
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations.
- Trial name
- BOREALIS-1 (NCT07021898)
- Testing
- ERAS-4001, ERAS-4001 in combination
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Erasca, Inc.
Cancer
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
This is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based…
- Trial name
- NCT03089554
- Testing
- Therapeutic Intervention
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Rachel Miller
High-grade Serous Ovarian Cancer, Circulating Tumor DNA
CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer.
- Trial name
- NCT05027828
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Rectal Cancer
Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy
feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma collection of response rate (T- and…
- Trial name
- NCT00671645
- Testing
- capecitabine, bevacizumab
- Where
- 10 sites in Austria
- Volunteers
- 8 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Non-Small Cell Lung Cancer, PET/CT
FAP-targeted PET/NIR in Lung Malignant Tumors
Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included.
- Conditions
- Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy
- Trial name
- NCT07498933
- Testing
- PET/CT scans
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Solid Tumor, Malignant Lymphoma
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
This is an open-label, Phase 1, dose escalation study of oral ARQ 092 administered to subjects with advanced solid tumors and recurrent malignant lymphoma.
- Conditions
- Solid Tumor, Malignant Lymphoma, Tumor
- Trial name
- NCT01473095
- Testing
- ARQ 092
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Advanced Solid Tumors, Metastatic Solid Tumors
Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid Tumors
Study Overview This study evaluates a proteogenomic screening platform to identify precise therapeutic targets for patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors, Locally Advanced Solid Tumors, Recurrent Solid Tumors
- Trial name
- K-PRECISION (NCT07891169)
- Testing
- Homologous Recombination Deficiency (HRD), ALK/ROS1/MET, standard care treatment
- Where
- 2 sites in South Korea
- Volunteers
- 2,800 people
- Sponsor
- National Cancer Center, Korea
Metastatic Breast Cancer
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain
HOPE Focus is an observational study that aims at promoting research against metastatic breast cancer by means of collective research led by patients (patient-centric trial).
- Trial name
- HOPE-Focus (NCT06991946)
- Testing
- Liquid Biopsy, Archival Tumor DNA
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- SOLTI Breast Cancer Research Group
Advanced Thyroid Cancer Patients Who Received Target Therapy
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer.
- Trial name
- NCT06195228
- Testing
- dabrafenib plus trametinib with or without PD-1 antibody, entrectinib or larotrectinib with or without anti-PD-1 antibdoy, pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
- Where
- 8 sites in China
- Volunteers
- 800 people
- Sponsor
- Fudan University
Penile Neoplasms, Carcinoma, Squamous Cell
Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis
Penile squamous cell carcinoma (SCC) is a very rare disease and prognosis depends primarily on regional lymph-node involvement. Despite the fact that cure can be obtained in patients with low metastatic load (pN1) by monotherapy…
- Trial name
- HER-Uro01 (NCT01728233)
- Testing
- Dacomitinib
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Sepsis, Emergent Infections, Treatment
Droplet Digital PCR Combines With Transcriptome Analysis in Early Warning of Sepsis in the Emergency Department
Rapid identification of pathogens and early warning of host response are key to improve the prognosis of sepsis. Establishing a comprehensive identification system based on pathogen identification and host immune status is an…
- Trial name
- NCT06028178
- Testing
- Droplet digital PCR
- Volunteers
- 360 people
- Sponsor
- Shanghai East Hospital